BA attenuated the decrease in the integrity and increase in the permeability of the epithelial barrier injury induced by LPS in Caco2 cell monolayers. by Luqiong Liu (11537092)

Changes in lactate/pyruvate ratio and ketone bodies ratio during CPB. by Vincent Pey (21433304)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Comparison of questionnaire scores among genotypes for the significant associations. by Dai Nogimura (21445649)

Subjects:

Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells. by Xiang-Fan Chen (13932983)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

FGF18 injections increase TIMP1 and decrease MMP13 and NOGGIN, suggesting healing of degeneration induction of anabolic effect. by Flavia Gomes Velasque Gama (21175112)

(a) Surface area and volume change with water level; (b) Topographic changes in the Caspian Sea. by Zihao Duan (17403792)

Subjects:

Summary of significant single-arm time effect. by Wensheng Xiao (16557866)

Relation between training-related changes in unipedal and bipedal stance. by Cristina Dolciotti (16317330)

Subjects:

Reducing Dscam1 diversity decreases adult lifespan in a cluster-specific manner, also see S6 and S7 Figs. by Haiyang Dong (4783608)

Potato gene ontology enrichment results significant at <i>p</i> < 0.01. by Margaret A. Carpenter (6104180)

Trends of incident opioid users, L-TOT users, and L-TOT discontinuers between 2009 and 2013. by Qian Cai (112039)

Subjects:

The yearly numerator, denominator and rate of incident opioid users, L-TOT users and L-TOT discontinuers from 2009 to 2019. by Qian Cai (112039)

Subjects:

Incidence rate ratios of negative binominal regression models for yearly rates of incident opioid users, L-TOT users and L-TOT discontinuers during 2009–2013 and 2015–2019. by Qian Cai (112039)

Subjects:

Demographic, comorbidity, concurrent drug, and opioid characteristics, among L-TOT users and L-TOT discontinuers between 2009–2019. by Qian Cai (112039)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

Log2 fold change (FC) of the overlaps of lipid metabolites between the study groups and those significant metabolites that appear exclusively in a single group (unique) represented... by Laia Bertran (3685147)